Get the Stockscreener App
397.27
0.16%
0.63
Vertex Pharmaceuticals Inc stock is traded at $397.27, with a volume of 5.78M.
It is up +0.16% in the last 24 hours and down -11.96% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$396.64
Open:
$395.72
24h Volume:
5.78M
Relative Volume:
4.43
Market Cap:
$102.31B
Revenue:
$10.63B
Net Income/Loss:
$-479.80M
P/E Ratio:
29.80
EPS:
13.33
Net Cash Flow:
$-1.35B
1W Performance:
-14.33%
1M Performance:
-11.96%
6M Performance:
-15.72%
1Y Performance:
-0.74%
1-Day Range:
$386.49
$401.31
1-Week Range:
$377.85
$474.19
52-Week Range:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein - Yahoo Finance
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally - The Motley Fool
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock - MSN
Vertex Pharmaceuticals (VRTX) Gains FDA Approval for ALYFTREK™ - GuruFocus.com
Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment - Reuters.com
Vertex Pharmaceuticals (VRTX) Stock Surges Amid Mixed Analyst Ra - GuruFocus.com
Vertex Pharmaceuticals announces FDA approval for ALYFTREK By Investing.com - Investing.com UK
Vertex Pharma (VRTX) Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - StreetInsider.com
Vertex Secures FDA Approval for Groundbreaking Once-Daily Cystic Fibrosis Treatment ALYFTREK - StockTitan
Vertex's TRIKAFTA Wins Major FDA Expansion for Cystic Fibrosis Treatment in Young Children - StockTitan
Barclays Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
BMO Capital Markets Lowers Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $520.00 - MarketBeat
HC Wainwright Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? - Yahoo! Voices
Is Vertex Stock A Sell After Non-Opioid Pain Drug Whiffs It? - Investor's Business Daily
Principal Financial Group Inc. Buys 21,649 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Oppenheimer Downgrades Vertex Pharmaceuticals (VRTX) After Study Results - GuruFocus.com
Vertex Plummets With Pain Drug No Better Than Placebo in Study - MSN
Cystic Fibrosis Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, and Key Companies involved by DelveInsight | Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharma - Barchart
Vertex’s Suzetrigine Disappoints In Phase II Pain Study, But Phase III Planning Under Way - Citeline News & Insights
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug - Yahoo! Voices
Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): ‘I Think You Should Buy The Dip Here’ - Insider Monkey
Vertex Pharmaceuticals (NASDAQ:VRTX) Lowered to "Market Perform" Rating by Oppenheimer - MarketBeat
Stocks on the Move: Vertex Pharma, Shake Shack, Zoom, Lennar and Home Depot - MSN
Oppenheimer downgrades Vertex after lumbosacral radiculopathy study - TipRanks
Bank of America Issues Pessimistic Forecast for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? - Yahoo Finance
Vertex’s stock hurt after non-opioid pain drug shows benefit similar to placebo - Yahoo Finance
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint - BioPharma Dive
Vertex's non-opioid pain drug no better than placebo in sciatica study - FirstWord Pharma
Accenture, Robinhood and Coinbase, Vertex: Market Minute - Yahoo Finance
Vertex Pharmaceuticals is Now Oversold (VRTX) - Nasdaq
Vertex stock plummets as study results show non-opioid pain drug no better than placebo - The Boston Globe
Vertex Pharmaceuticals Stock Heads for Worst Day in 4 Years - Schaeffers Research
Vertex's $10 Billion Blow: Painkiller Trial Results Spark Invest - GuruFocus.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Hits New 52-Week LowWhat's Next? - MarketBeat
Vertex Pharmaceuticals Inc. (VRTX) Investigated For - GlobeNewswire
Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton ... - The Bakersfield Californian
Vertex Pain Drug Doesn’t Beat Placebo. The Company Says It Still Sees Promise. - Barron's
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results - MSN
Vertex's $10 Billion Blow: Painkiller Trial Results Spark Investor Panic - Yahoo Finance
Vertex's painkiller results match placebo in study, shares tumble - Reuters.com
Vertex Phase II suzetrigine study disappoints - The Pharma Letter
Vertex Dips on Mixed Phase II Data for Non-Opioid Pain Therapy - BioSpace
Vertex stock touches 52-week low at $389.73 amid market shifts - Investing.com UK
Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3 - Yahoo Finance
Vertex’s non-opioid painkiller meets trial goal — but investors aren’t sold - The Business Journals
Vertex Pharma’s suzetrigine meets Phase 2 primary endpoint in radiculopathy - TipRanks
Vertex's pain trial hits endpoint but sinks stock as placebo comparison spooks investors - Fierce Biotech
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
2.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):